Diagnosis of Low Bone Mass Density: Serological Versus Radiological Methods

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2022 Jul 8

PMID 35799999

Authors

Osama A Shaikhomar

Abdelghnay H Abdelghnay

Haitham M H Qutob

Affiliations

Soon will be listed here.

Abstract

Context: Bone remodeling comprises balanced coupling of bone formation and resorption, and low bone mineral density (BMD) demonstrates high rates of bone resorption. Osteoporosis is a chronic asymptomatic disease with fragile bones and impending risk of fractures mediated by minor trauma. Whereas bone mineralization and integrity are determined by calcium and vitamin D, specific serum markers such as bone specific alkaline phosphatase (ALP) and osteocalcin (OC) play a vital role in bone formation.

Materials And Methods: Serum calcium, vitamin D, ALP, and OC levels were measured in 2,145 Saudi students aged 18-22 years at Umm Al-Qura University. The BMD was measured by dual-energy X-ray absorptiometry (DEXA), and the findings were statistically evaluated. The following statistics were utilized in the analysis: the SPSS software was used to record, tabulate, and statistically evaluate the results.

Results: Low BMD cases accounted for 27.46% of all cases investigated, with considerably higher serum calcium, bone-specific ALP, and OC levels compared to control cases, but significantly lower serum vitamin D levels. In low BMD instances, there was no association between serum markers and DEXA findings.

Conclusion: Serum indicators by themselves may be useful for screening and predicting patients at risk of osteoporosis, as well as assessing treatment response. The combination of serum markers and DEXA measures is more effective in detecting low BMD.

References

Siddiqui J, Partridge N . Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement. Physiology (Bethesda). 2016; 31(3):233-45. PMC: 6734079. DOI: 10.1152/physiol.00061.2014. View

Yedavally-Yellayi S, Ho A, Patalinghug E . Update on Osteoporosis. Prim Care. 2019; 46(1):175-190. DOI: 10.1016/j.pop.2018.10.014. View

Bayard F, Bec P, LOUVET J . Measurement of plasma 25-hydroxycholecalciferol in man. Eur J Clin Invest. 1972; 2(4):195-8. DOI: 10.1111/j.1365-2362.1972.tb00644.x. View

Eastell R, Szulc P . Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol. 2017; 5(11):908-923. DOI: 10.1016/S2213-8587(17)30184-5. View

Reid I . Vitamin D Effect on Bone Mineral Density and Fractures. Endocrinol Metab Clin North Am. 2017; 46(4):935-945. DOI: 10.1016/j.ecl.2017.07.005. View

Kuo T, Chen C . Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017; 5:18. PMC: 5436437. DOI: 10.1186/s40364-017-0097-4. View

Hicks R, Umnitz L, Seibert D . Hypophosphatasia: A rare disorder. J Am Assoc Nurse Pract. 2018; 30(11):600-602. DOI: 10.1097/JXX.0000000000000149. View

Cano A, Chedraui P, Goulis D, Lopes P, Mishra G, Mueck A . Calcium in the prevention of postmenopausal osteoporosis: EMAS clinical guide. Maturitas. 2017; 107:7-12. DOI: 10.1016/j.maturitas.2017.10.004. View

Haglin J, Jain S, Eltorai A, Daniels A . Bone Growth Stimulation: A Critical Analysis Review. JBJS Rev. 2017; 5(8):e8. DOI: 10.2106/JBJS.RVW.16.00117. View

10.

Diemar S, Mollehave L, Quardon N, Lylloff L, Thuesen B, Linneberg A . Effects of age and sex on osteocalcin and bone-specific alkaline phosphatase-reference intervals and confounders for two bone formation markers. Arch Osteoporos. 2020; 15(1):26. DOI: 10.1007/s11657-020-00715-6. View

11.

Bauer D . Clinical Use of Bone Turnover Markers. JAMA. 2019; 322(6):569-570. DOI: 10.1001/jama.2019.9372. View

12.

Shetty S, Kapoor N, Bondu J, Thomas N, Paul T . Bone turnover markers: Emerging tool in the management of osteoporosis. Indian J Endocrinol Metab. 2016; 20(6):846-852. PMC: 5105571. DOI: 10.4103/2230-8210.192914. View

13.

Mukaiyama K, Kamimura M, Uchiyama S, Ikegami S, Nakamura Y, Kato H . Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin Exp Res. 2014; 27(4):413-8. DOI: 10.1007/s40520-014-0296-x. View

14.

Wenz I, Reissmann R, BORNIG H . Determination of osteocalcin in serum by an ultramicro-ELISA with alkaline phosphatase as marker enzyme. Biomed Biochim Acta. 1991; 50(2):145-9. View

15.

Paschalis E, Gamsjaeger S, Hassler N, Fahrleitner-Pammer A, Dobnig H, Stepan J . Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality. Bone. 2016; 95:41-46. DOI: 10.1016/j.bone.2016.11.002. View

16.

Gkiatas I, Lykissas M, Kostas-Agnantis I, Korompilias A, Batistatou A, Beris A . Factors affecting bone growth. Am J Orthop (Belle Mead NJ). 2015; 44(2):61-7. View

17.

Hannemann A, Friedrich N, Spielhagen C, Rettig R, Ittermann T, Nauck M . Reference intervals for serum osteocalcin concentrations in adult men and women from the study of health in Pomerania. BMC Endocr Disord. 2013; 13:11. PMC: 3606466. DOI: 10.1186/1472-6823-13-11. View

18.

Spustova V, Dzurik R . [Vitamin D: synthesis, metabolism, regulation, and an assessment of its deficiency in patients with chronic renal disease]. Vnitr Lek. 2004; 50(7):537-43. View

19.

Behr W, Barnert J . Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin Chem. 1986; 32(10):1960-6. View

20.

Vs K, K P, Ramesh M, Venkatesan V . The association of serum osteocalcin with the bone mineral density in post menopausal women. J Clin Diagn Res. 2013; 7(5):814-6. PMC: 3681044. DOI: 10.7860/JCDR/2013/5370.2946. View